Evidence map›Paper›PMID 36677018›Full record

ArticleMetabolites2023

Identification of Potential

Mohamed A A Orabi, Mohammed Merae Alshahrani, Ahmed M Sayed, Mohamed E Abouelela, Khaled A Shaaban, El-Shaymaa Abdel-Sattar

Abstract read
In one paragraph

Article in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Research in pharmaceutical sciences · 2026
    Article
  2. Silver-Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Molecules (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Molecular Docking and Molecular Dynamics Simulations in Related toTropical medicine and infectious disease · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed A A OrabiDepartment of Pharmacognosy, College of Pharmacy, Najran University, Najran 61441, Saudi Arabia.ORCID 0000-0002-4288-6829
Mohammed Merae AlshahraniDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, Najran 61441, Saudi Arabia.ORCID 0000-0002-9387-5492
Ahmed M SayedDepartment of Pharmacognosy, Faculty of Pharmacy, Nahda University, Beni-Suef 62513, Egypt.ORCID 0000-0002-1442-183X
Mohamed E AbouelelaDepartment of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University, Assiut-Branch, Assiut 71524, Egypt.ORCID 0000-0002-9489-234X
Khaled A ShaabanCenter for Pharmaceutical Research and Innovation, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA.ORCID 0000-0001-7638-4942
El-Shaymaa Abdel-SattarDepartment of Medical Microbiology and Immunology, Faculty of Pharmacy, South Valley University, Qena 83523, Egypt.

Funding

Deanship of Scientific Research at Najran University, Saudi Arabia NU/NRP/MRC/11/8.
6 · The paper itself

Abstract

Leishmaniasis is a group of infectious diseases caused by

Indexed as

leishmaniasisL. majormolecular dockingmolecular dynamicsN-myristoyltransferase

Identifiers

PMID36677018
PMCPMC9861338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.